Gilead Sciences, Inc. bought $15.0M of Arcus Biosciences (RCUS)
Executed Feb 18 2025, disclosed Feb 20 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 20 2025), the stock returned -17.3% (delay-adjusted); from the execution session (Feb 18 2025), -29.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Gilead Sciences, Inc. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in ASMB. Across 1 priced purchase filing, the average 21-session return was +7.0% from execution and +30.6% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 56 days.
Healthcare · Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→